Summary
Craif raises $22M to expand early cancer detection software into US market. The company uses microRNA to develop AI-powered software that detects cancer at early stage. Software is non-invasive and can be conducted from home.
Key Points
Craif's software detects cancer using microRNA
The software is non-invasive and can be conducted from home
Craif has raised $22 million in series C funding to expand into US market
The company plans to use the funds to complete trials in US by 2026-end
Why It Matters
Early cancer detection is crucial for effective treatment and improved patient outcomes. Craif's AI-powered software has the potential to revolutionize cancer diagnosis and improve healthcare outcomes.
Author
Kate Park